Drug Trial Radar · NCT03032172
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy
Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
174
Actual
Start
Mar 3, 2017
Primary completion
Feb 7, 2025
Study completion Feb 7, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, exploratory, non-comparative, and open-label study to investigate the safety, tolerability, PK, and PK/PD relationship of risdiplam in adults, children and infants with Spinal Muscular Atrophy (SMA) previously enrolled in Study BP29420 (Moonfish) with the splicing modifier RO6885247 or previously treated with nusinersen, olesoxime or AVXS-101.
Conditions
- Spinal Muscular Atrophy
Interventions
RisdiplamDrug
Risdiplam will be administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Baseline up to 5 years
- Number of Participants Who Discontinued Treatment Due to AEsTime frame: Baseline up to 5 years
- Number of Participants With Shift in Puberty Status From BaselineTime frame: Baseline, Week 52, 104, 156, 208 and 260
- Number of Participants With Protocol-defined Neurological Conditions (NC)Time frame: Baseline up to Week 260
- Number of Participants With Emergence or Worsening of Symptoms as Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to approximately 5 years
- Anthropometric Examination: Change From Baseline in WeightTime frame: Baseline up to Week 260
- Anthropometric Examination: Change From Baseline in HeightTime frame: Baseline up to Week 260
- Anthropometric Examination: Change From Baseline in Head CircumferenceTime frame: Baseline up to Week 208
- Maximum Plasma Concentration (Cmax) of RisdiplamTime frame: Predose on Weeks 2, 4, 13, 26, 39, 52, 65, 91 and post-dose on Weeks 1, 4, 13, 52, 91 and 104
- Area Under the Concentration-Time Curve (AUC0-24h) of RisdiplamTime frame: 24 hours Postdose at Year 2 Visit
- Plasma Trough Concentration (Ctrough) of RisdiplamTime frame: Predose at Year 5 visit
Locations
24 sites in 9 countries. Site status is shown where the registry gives one.
Stanford University Medical Center
Palo Alto, California
Nemours Children's Hospital
Orlando, Florida
Boston Childrens Hospital
Boston, Massachusetts
Columbia University Medical Center
New York, New York
UZ Gent
Ghent, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Hopital Femme Mere Enfant
Bron, France
Hopital Roger Salengro
Lille, France
CHRU de Montpellier, Hopital Gui de Chauliac
Montpellier, France
Hôpital Necker-Enfants Malades
Paris, France
Hopital des Enfants
Toulouse, France
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
IRCCS Ospedale Pediatrico Bambino Gesù
Rome, Lazio, Italy
Policlinico Agostino Gemelli
Rome, Lazio, Italy
IRCCS Istituto Giannina Gaslini
Genoa, Liguria, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
UOSD Malattie Neurodegenerative
Messina, Sicily, Italy
UMC Utrecht
Utrecht, Netherlands
Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
Warsaw, Poland
Universitäts-Kinderspital (UKBB) Neuropädiatrie
Basel, Switzerland
Birmingham Heartlands Hospital
Birmingham, United Kingdom
UCL Institute of Child Health & Great Ormond Street Hospital for Children
London, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.